Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03171064
Recruitment Status : Recruiting
First Posted : May 31, 2017
Last Update Posted : March 25, 2020
Sponsor:
Collaborator:
Department of Dermatology, Heidelberg University Hospital
Information provided by (Responsible Party):
Joachim Wiskemann, University Hospital Heidelberg

Brief Summary:
Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma. Numerous high quality studies demonstrate that endurance and resistance training in cancer patients is safe and elicits beneficial effects. However, there is no systematic experience with regard to exercise interventions in patients undergoing checkpoint inhibitor treatment. Therefore, the Sportivumab Study aimed to investigate safety, feasibility and effectivity of a 12 week combined resistance and endurance exercise intervention program during checkpoint inhibitor treatment. It is planned to enroll 40 patients. Participants will be randomized into an experimental and a wait-list control group (20 per group). The wait-list control group will receive the exercise intervention program after week 13 of enrollment.

Condition or disease Intervention/treatment Phase
PD-1 Antibodies Exercise Melanoma Behavioral: Resistance and Endurance Exercise Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
Actual Study Start Date : September 5, 2017
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : March 1, 2021


Arm Intervention/treatment
Experimental: Experimental intervention arm (EX)
The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
Behavioral: Resistance and Endurance Exercise
Machine-based, 2x/week endurance and resistance training for 12 weeks

No Intervention: Wait list - control group (UC)
Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.



Primary Outcome Measures :
  1. Feasibility of the exercise intervention [ Time Frame: During 12 week of the intervention ]
    Participants ability to fulfill the exercise prescription (measured by % of training frequency, intensity and duration as well as type of the exercise) during immune checkpoint inhibitor treatment with a PD-1 antibody +/- ipilimumab


Secondary Outcome Measures :
  1. Quality of life [ Time Frame: During 12 week of the intervention ]
    Quality of life (QoL) will be assessed with the validated 30-item self-assessment questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30, version 3.0). It includes five multi-item functional scales (physical, role, emotional, cognitive, and social function), three multi-item symptom scales (fatigue, pain, nausea/vomiting), and six single items assessing further symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) and financial difficulties.

  2. Fatigue [ Time Frame: During 12 week of the intervention ]
    Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI) which is a 20-item, multidimensional self-assessment questionnaire that has been validated for a German-speaking population.It covers five different dimensions of fatigue (general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue).

  3. Sleep Quality [ Time Frame: During 12 week of the intervention ]
    Sleep quality and sleep problems will be assessed with the validated and frequently used Pittsburgh Sleep Quality Index (PSQI).

  4. Depression [ Time Frame: During 12 week of the intervention ]
    Depressive symptoms are assessed with the 20-item Center for Epidemiological Studies Depression Scale (CES-D).

  5. Physical Activity Behavior [ Time Frame: During 12 week of the intervention ]
    Physical activity (PA) behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Short QUestionnaire to ASsess Health-enhancing PA (SQUASH) which has the advantage that it is short and easy to complete.

  6. Cardiopulmonary Fitness [ Time Frame: During 12 week of the intervention ]
    Cardiopulmonary fitness will be measured by assessing maximal aerobic capacity (VO2peak) via a maximal incremental cycling test with a quasi-ramp protocol starting at 20 watts and increasing by 10 watts every minute until volitional exhaustion. To control for test validity gas exchange will be measured using a breath-by-breath gas analysis system which will be calibrated according to the instructions of the manufacturer before each test. To monitor patient safety, a 12-lead electrocardiogram (ECG) will be and blood pressure will be measured prior, during and after testing. The criteria for exhaustion will be fulfilled if two out of three of the following criteria are valid: (1) Borg scale > 16; (2) peak heart rate ± 10% of age-appropriate reference value and/or (3) respiratory exchange ratio (RER) > 1.1. Exercise will be terminated prematurely in the case of major ECG abnormalities, severe dyspnea or excessive blood pressure increase (≥250 mmHg systolic and/or ≥110 mmHg diastolic).

  7. Muscle strength [ Time Frame: During 12 week of the intervention ]
    Isometric (in four different joint angle positions) and isokinetic (at 60° angle speed) muscle capacity is measured with the Isomed 2000® diagnostic module (isokinetic evaluation and training machine). The protocol includes testing of representative muscles groups for upper (elbow flexors/extensors) and lower extremity (knee extensors/flexors)

  8. Pain [ Time Frame: During 12 week of the intervention ]
    The Brief Pain Inventory (BPI) is a 14-item questionnaire developed for use in patients with cancer that assesses worst pain, pain severity, and pain interference over the past week, reported on a scale of 0 to 10. Worst pain is categorized as mild (score of 3 to 4), moderate (score of 5 to 7), or severe pain (score of 8 to 10). Pain severity is measured as the average of responses to questions on worst pain, average pain, least pain, and pain right now. Pain interference is the average of seven interference items, such as walking, mood, and sleep.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients at age ≥ 18 years
  • Diagnosed with melanoma stage (independent of stage)
  • Assigned to receive an immunotherapeutic regimen (PD-1 antibody +/- Ipilimumab)
  • Sufficient German language skills
  • Willing to train at the exercise facilities twice per week and to take part in the scheduled testing at the National Center for Tumor Diseases
  • Signed informed consent

Exclusion Criteria:

  • Any physical or mental conditions that would hamper the performance of the training programs or the completion of the study procedures
  • Engaging in systematic intense exercise training (at least 1h twice per week)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03171064


Contacts
Layout table for location contacts
Contact: Joachim Wiskemann, Dr +49 6221 565904 joachim.wiskemann@nct-heidelberg.de
Contact: Friederike Rosenberger, Dr. +49 6221 56 35681 friederike.scharhag-rosenberger@nct-heidelberg.de

Locations
Layout table for location information
Germany
Heidelberg University Clinic Recruiting
Heidelberg, Germany, 69120
Contact: Jessica Hassel, MD    062215635681    jessica.hassel@med.uni-heidelberg.de   
Contact: Friederike Rosenberger, PhD    062215635681    friederike.rosenberger@nct-heidelberg.de   
Sponsors and Collaborators
University Hospital Heidelberg
Department of Dermatology, Heidelberg University Hospital
Layout table for additonal information
Responsible Party: Joachim Wiskemann, Dr. Joachim Wiskemann, University Hospital Heidelberg
ClinicalTrials.gov Identifier: NCT03171064    
Other Study ID Numbers: Sportivumab/S-103/2017
First Posted: May 31, 2017    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Maybe pooling data with a comparable project in the united states

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Joachim Wiskemann, University Hospital Heidelberg:
Exercise
Cancer
Melanoma
Feasibility
PD-1 antibodies
Checkpoint inhibitors
Immune system
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas